Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Targovax and Oslo University Hospital Announce Collaboration To Test TG Mutant RAS Vaccination in Multiple Myeloma
Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid […]
Ultomiris Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab-cwvz) achieved a statistically […]
Curebase Secures $40 Million in Series B Funding
Curebase, a company committed to democratizing access to clinical studies, has raised $40 million in […]
Strong Demand for Lung Intelligence Accelerates VIDA's Growth
VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence, announced it has secured […]
Amniotics AB Announces Positive Pre-clinical Proof-of-concept Results for PulmoStem™ in End-stage Lung Disease
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that PulmoStem™ significantly reduces the incidence of […]
Major Journal Publishes Landmark Proteomics Study Demonstrating Development of an Unprecedented New Clinical Cardiovascular Risk Test
In one of the largest proteomic studies ever conducted and published April 6 in the […]
Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined […]
Alex Therapeutics Raises €3.5M in Oversubscribed Financing round from Top Tier VC Investors to Advance Expansion in Europe and the US.
Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics today announces it has secured a €3.5M funding round, led […]
CellCentric Strengthens Leadership Team
CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, […]
Amniotics Receives Approval for Phase I/II Study of Pulmostem™ in Hospitalized COVID-19 Patients
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received approval by regulatory […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more